Please ensure Javascript is enabled for purposes of website accessibility

Why Ardelyx Inc Skyrocketed Higher Today

By Brian Orelli, PhD - Oct 12, 2017 at 5:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive phase 3 data for the biotech's irritable bowel syndrome drug, tenapanor, sends shares higher.

What happened

Ardelyx (ARDX 0.69%) stock rose 44% on Thursday after the company announced positive data from the phase 3 T3MPO-2 trial testing its irritable bowel syndrome drug, tenapanor, after the close of the bell last night.

So what

Of the patients taking tenapanor, 36.5% were deemed responders, a statically significant increase over the 23.7% responder rate for patients taking placebo. Responders were defined as having at least a 30% reduction in abdominal pain and an increase of one or more complete spontaneous bowel movements in the same week for at least six of the 12 weeks of the treatment period.

Woman's torso while she holds her stomach

Image source: Getty Images.

The responder rate was the primary endpoint of the study, so you could stop there and call it a success, but parsing the data further reveals more good news for Ardelyx. Looking at pain and bowel movements separately, tenapanor was better than placebo for both measurements individually. In Ardelyx's first phase 3 trial for tenapanor, the drug met the combined responder rate primary endpoint and improved abdominal pain individually, but didn't show a statistically significant increase in bowel movements alone. The better performance for the second trial probably explains some of today's jump in stock price.

Using the more stringent requirements of responding for nine out of the 12 treatment weeks, tenapanor also had a higher responder rate of 18.4%, compared to 5.3% for placebo. Tenapanor improved pain and bowel movements when looked at separately with the more stringent measurement of nine out of 12 weeks as well.

Now what

With a second positive phase 3 trial for tenapanor, Ardelyx is on track to submit a marketing application to the Food and Drug Administration in the second half of 2018.

While the efficacy data looks good enough to get past the FDA, the drug does create a high level of diarrhea: 16% compared to 3.7% for patients taking placebo. Diarrhea isn't the worst side effect -- especially relative to having pain because the patient can't have a bowel movement -- but it may make a difference after tenapanor is approved and has to compete with other irritable bowel syndrome drugs.

The placebo adjusted discontinuation rate due to diarrhea was 5.8% in this trial, while, for example, 5% of patients taking Ironwood Pharmaceuticals and Allergan's Linzess in its pivotal trials discontinued due to diarrhea. We'll have to wait and see whether a percentage point or so increase in severe diarrhea is enough to make a difference to prescribers.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ardelyx, Inc. Stock Quote
Ardelyx, Inc.
$0.59 (0.69%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.